- Investors & Media
- Investors & Media
- Contact Us
Kamada announced today preliminary and unaudited total revenues for the fourth quarter and full-year 2018. Total revenue for the fourth quarter of 2018 is expected to be between $46.7 million and $48.7 million. Total revenue for full-year 2018 is expected to be between $113 million and $115 million.
Kamadad announced today financial results for the three and nine months ended September 30, 2018.
Kamada announced today the appointment of Eitan Kyiet as Vice President of Business Development. Mr. Kyiet has over 20 years of experience in business development, strategic operations and corporate law, with a significant portion of his career spent in the life sciences industry. He will lead Kamada’s business development and strategic commercial activities, with a focus on advancing market opportunities for the Company’s products. Mr. Kyiet will report directly to Amir London, Kamada’s Chief Executive Officer.
Kamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation.
As result of the recent labor strike part of 2018 shipments are likely to be delayed to early 2019 Subsequent update and full-year 2019 revenue guidance to be provided later this year.
Kamada announced that on August 15, 2018, the Company, the Employees’ Committee of Kamada’s Beit Kama production facility in Israel (the “Employee’s Committee”), the Histadrut – General Federation of Labor in Israel (the “Histadrut”), and a Mediator appointed by the parties (the “Mediator”), signed a binding Memorandum of Understanding (the “Binding MoU”) that terminates the previously disclosed labor strike.
Kamada announced financial results for the three and six months
ended June 30, 2018.
Kamada announced that it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the development plan for its proposed pivotal Phase 3 study for its proprietary Inhaled Alpha-1 Antitrypsin therapy (Inhaled AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD).
Since 1967, the lives of countless babies have been saved by the pioneering Rh Program – and to date, millions of doses of anti-D have been given to Rh negative women.
The results from the Company’s Phase 2 trial of Alpha-1 Antitrypsin (AAT) in newly diagnosed type-1 diabetes (T1D) will be presented in an oral session at the 78th Scientific Sessions of the American Diabetes Association (ADA).